Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Receivables: 2015-2025

Historic Change in Receivables for Cartesian Therapeutics (RNAC) over the last 8 years, with Sep 2025 value amounting to $368,000.

  • Cartesian Therapeutics' Change in Receivables rose 101.35% to $368,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year decrease of 5852.17%. This contributed to the annual value of -$5.0 million for FY2024, which is 588.43% down from last year.
  • Latest data reveals that Cartesian Therapeutics reported Change in Receivables of $368,000 as of Q3 2025, which was up 126.08% from -$1.4 million recorded in Q2 2025.
  • Cartesian Therapeutics' Change in Receivables' 5-year high stood at $30.0 million during Q2 2024, with a 5-year trough of -$27.2 million in Q3 2024.
  • Moreover, its 3-year median value for Change in Receivables was -$487,000 (2023), whereas its average is -$534,000.
  • In the last 5 years, Cartesian Therapeutics' Change in Receivables surged by 13,591.87% in 2022 and then tumbled by 5,487.27% in 2024.
  • Cartesian Therapeutics' Change in Receivables (Quarterly) stood at $2.6 million in 2021, then plummeted by 112.70% to -$329,000 in 2022, then skyrocketed by 395.44% to $972,000 in 2023, then slumped by 507.10% to -$4.0 million in 2024, then soared by 101.35% to $368,000 in 2025.
  • Its last three reported values are $368,000 in Q3 2025, -$1.4 million for Q2 2025, and $893,000 during Q1 2025.